IL2RA and neoplasm: As a proof of concept, camidanlumab tesirine, a DNA-damaging toxin that is based on pyrrolobenzodiazepine (PBD) dimer and targeting CD25, is the first antibody-drug conjugate (ADC) as immunotherapeutic agent to directly target immune cells rather than tumor cells.